Survey on human papillomavirus/p16 screening use in oropharyngeal carcinoma patients in the United States

Cancer

Volumn 116, Issue 2, 2010, Pages 514-519

  Shoushtari, Asal N ^a   Rahimi, Nina P ^a   Schlesinger, David J ^b   Read, Paul W ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Head and neck cancers; Human papillomavirus DNA screening; Intensity modulated radiotherapy; Oropharyngeal carcinoma; P16 DNA screening; P16 human papillomavirus DNA screening; Survey

Indexed keywords

VIRUS DNA;

ARTICLE; CONTROLLED STUDY; E-MAIL; GENERAL PRACTITIONER; HUMAN PAPILLOMAVIRUS TYPE 16; INTENSITY MODULATED RADIATION THERAPY; OROPHARYNX CARCINOMA; PATIENT CARE; PRIORITY JOURNAL; QUESTIONNAIRE; UNITED STATES;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, VIRAL; HEALTH CARE SURVEYS; HUMANS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; RADIATION ONCOLOGY;

EID: 75649097469     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24752     Document Type: Article

References (30)

1. American Cancer Society. Cancer Reference Information. Atlanta, Ga: American Cancer Society; 2008. Available at: http://www.cancer.org/docroot/STT/ stt-0-2008.asp?sitearea= STT&level=1 Accessed May 2, 2009.
2. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26:612-619.
3. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol. 2008;26:2606-2611.
4. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer. 2007;110:1429-143
5. Reimers N, Kasper HU, Weissenborn SJ, et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer. 2007;120: 1731-1738.
6. Li W, Thompson CH, Cossart YE, et al. The expression of key cell cycle markers and presence of human papillomavirus in squamous cell carcinoma of the tonsil. Head Neck. 2004;26:1-9.
7. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 2006;24:736-747.
8. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100:261-269.
9. Nichols AC, Faquin WC, Westra WH, et al. HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg. 2009;140:228-234.
10. Klozar J, Kratochvil V, Salakova M, et al. HPV status and regional metastasis in the prognosis of oral and oropharyngeal cancer. Eur Arch Otorhinolaryngol. 2008;265(suppl 1): S75-S82.
11. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000; 92:675-677.
12. Chang J, Hilsenbeck SG. Prognostic and predictive markers. In Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2004:675-696.
13. Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3655 invasive breast carcinomas. Am J Clin Pathol. 2005;123:541-546.
14. Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P. Correlation of HER-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J. 2005;11:278-280.
15. Wood WC, Muss HB, Solin LJ, Olopade OL. Malignant tumors of the breast. In Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principals and Practice of Oncology. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005: 1415-1477.
16. Wiseman SM, Makretsov N, Nielsen TO, et al. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer. 2005; 103:1770-1777.
17. Clark GM, McGuire WL. Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol. 1988;15(2 suppl 1):20-25.
18. Lee WT, Tubbs RR, Teker AM, et al. Use of in situ hybridization to detect human papillomavirus in head and neck squamous cell carcinoma patients without a history of alcohol or tobacco. Arch Pathol Lab Med. 2008;132:1653-1656.
19. Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX. Involvement of intact HPV 16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene. 2002;21:1510-1517.
20. Wittekindt C, Gultekin E, Weissenborn SJ, Dienes HP, Pfister HJ, Klussmann JP. Expression of p16 protein is associated with human papillomavirus status in tonsillar carcinomas and has implications on survival. Adv Otorhinolaryngol. 2005;62:72-80.
21. Niedobitek G, Pitteroff S, Herbst H, et al. Detection of human papillomavirus type 16 DNA in carcinomas of the palatine tonsil. J Clin Pathol. 1990;43:918-921.
22. National Comprehensive Cancer Network Guidelines. Head and Neck Cancer Guidelines. Available at: http://www. nccn.org/professionals/physician-gls/PDF/ head-and-neck. pdf Accessed February 25, 2009.
23. Mell LK, Roeske JC, Mundt AJ. A survey of intensitymodulated radiation therapy use in the United States. Cancer. 2003;98:204-211.
24. Mell LK, Mehrotra AK, Mundt AJ. Intensity-modulated radiation therapy use in the U.S., 2004. Cancer. 2005;104: 1296-1303.
25. Wong G, Webster AC, Chapman JR, Craig JC. Reported cancer screening practices of nephrologists: results from a national survey. Nephrol Dial Transplant. 2009;24:2136-2143.
26. Nieder A, Lotan Y, Nuss G, et al. Are patients with hematuria appropriately referred to urology? A multi-institutional questionnaire based survey. Urol Oncol. 2008 Dec 19. [Epub ahead of print].
27. Chao KS, Markman J, Haynie J, et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or 3-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys. 2001;49:907-916.
28. Chao KS, Huang CJ, Simpson JR, et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol. 2001;61:275-280.
29. Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA. Xerostomia and its predictors following parotidsparing irradiation of head-and neck cancer. Int J Radiat Oncol Biol Phys. 2001;50:695-704.
30. Henson BS, Eisbruch A, Ship JA. Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy. Oral Oncol. 2001;37:84-93.